Using the molecular classification of glioblastoma to inform personalized treatment

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 165-177

  Olar, Adriana ^a   Aldape, Kenneth D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

1p 19q; EGFR; FGFR; glioblastoma; IDH; mesenchymal; MGMT; pathogenesis; proneural; TACC

Indexed keywords

AGI 5198; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CCAAT ENHANCER BINDING PROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE 4; ERLOTINIB; GEFITINIB; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NIMOTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; EXON; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; TUMOR MICROENVIRONMENT;

1P/19Q; EGFR; FGFR; GLIOBLASTOMA; IDH; MESENCHYMAL; MGMT; PATHOGENESIS; PRONEURAL; TACC;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84890275818     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4282     Document Type: Review

References (149)

1. Louis DN, Ohgaki H, Wiestler OD, et al., WHO Classification of Tumors of the Central Nervous System, 4th edn. IARC: Lyon, France, 2007.
2. Phillips HS, Kharbanda S, Chen R, et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
3. Verhaak RG, Hoadley KA, Purdom E, et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
4. Zheng S, Chheda MG, Verhaak RG,. Studying a complex tumor: potential and pitfalls. Cancer J 2012; 18: 107-114.
5. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
6. Dolecek TA, Propp JM, Stroup NE, et al., CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncol 2012; 14: v1-49.
7. Ohgaki H, Kleihues P,. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453.
8. Ohgaki H, Kleihues P,. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
9. Olar A, Raghunathan A, Albarracin CT, et al., Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol 2012; 16: 161-170.
10. Rong Y, Post DE, Pieper RO, et al., PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 1406-1413.
11. Rak J, Milsom C, May L, et al., Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32: 54-70.
12. Rong Y, Durden DL, Van Meir EG, et al., 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006; 65: 529-539.
13. Forsythe JA, Jiang BH, Iyer NV, et al., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
14. Brat DJ, Castellano-Sanchez AA, Hunter SB, et al., Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920-927.
15. Lai A, Tran A, Nghiemphu PL, et al., Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29: 142-148.
16. Chinot O, Wick W, Mason W, et al., Phase III Trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in Avaglio. Neuro-oncology 2012; 14: vi101-105.
17. Friedman HS, Prados MD, Wen PY, et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
18. Norden AD, Young GS, Setayesh K, et al., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779-787.
19. de Groot JF, Fuller G, Kumar AJ, et al., Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 2010; 12: 233-242.
20. Narayana A, Kunnakkat S, Chacko-Mathew J, et al., Bevacizumab in recurrent high-grade pediatric gliomas. Neuro-oncology 2010; 12: 985-990.
21. Scott B, Quant E, McNamara M, et al., Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-oncology 2010; 12: 603-607.
22. Ricci-Vitiani L, Pallini R, Biffoni M, et al., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
23. Wang R, Chadalavada K, Wilshire J, et al., Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
24. Soda Y, Marumoto T, Friedmann-Morvinski D, et al., Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 2011; 108: 4274-4280.
25. Takano S., Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 2012; 29: 73-86.
26. Piao Y, Liang J, Holmes LS, et al., Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013; 19: 4392-4403.
27. Bhat KP, Salazar KL, Balasubramaniyan V, et al., The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25: 2594-2609.
28. Carro MS, Lim WK, Alvarez MJ, et al., The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318-325.
29. Cooper LA, Gutman DA, Chisolm C, et al., The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 2012; 180: 2108-2119.
30. Zoller M., CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
31. Bhat KPL, Veerakumar B, Vaillant B, et al., Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013; 24: 331-346.
32. Mantovani A, Allavena P, Sica A, et al., Cancer-related inflammation. Nature 2008; 454: 436-444.
33. Yeung Y, McDonald K, Grewal T, et al., Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 2013; 168: 591-606.
34. Lu T, Tian L, Han Y, et al., Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways. Proc Natl Acad Sci USA 2007; 104: 4365-4370.
35. Yeung YT, Bryce NS, Adams S, et al., p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. J Neurooncol 2012; 109: 35-44.
36. Sharma V, Dixit D, Koul N, et al., Ras regulates interleukin-1β- induced HIF-1α transcriptional activity in glioblastoma. J Mol Med (Berl) 2011; 89: 123-136.
37. Tchirkov A, Rolhion C, Bertrand S, et al., IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 2001; 85: 518-522.
38. Tchirkov A, Khalil T, Chautard E, et al., Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 2007; 96: 474-476.
39. Inda M-d-M, Bonavia R, Mukasa A, et al., Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-1745.
40. Bonavia R, Inda MM, Vandenberg S, et al., EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene 2012; 31: 4054-4066.
41. Galli R, Binda E, Orfanelli U, et al., Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
42. Singh SK, Hawkins C, Clarke ID, et al., Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
43. Singh SK, Clarke ID, Terasaki M, et al., Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
44. Ignatova TN, Kukekov VG, Laywell ED, et al., Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193-206.
45. Pallini R, Ricci-Vitiani L, Banna GL, et al., Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 8205-8212.
46. Lathia JD, Gallagher J, Myers JT, et al., Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PloS One 2011; 6: e24807.
47. Alcantara Llaguno S, Chen J, Kwon CH, et al., Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009; 15: 45-56.
48. Lathia JD, Heddleston JM, Venere M, et al., Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011; 8: 482-485.
49. Zhou BB, Zhang H, Damelin M, et al., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
50. Beier D, Schulz JB, Beier CP,. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 2011; 10: 128.
51. Bao S, Wu Q, McLendon RE, et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
52. + cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
53. Gong X, Schwartz PH, Linskey ME, et al., Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology 2011; 76: 1126-1134.
54. Chen J, Li Y, Yu T-S, et al., A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-526.
55. Ohgaki H, Kleihues P,. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 2011; 28: 177-183.
56. Nobusawa S, Watanabe T, Kleihues P, et al., IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-6007.
57. Watanabe T, Nobusawa S, Kleihues P, et al., IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
58. Cancer, Genome, Atlas, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
59. Parsons DW, Jones S, Zhang X, et al., An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
60. Jiao Y, Killela PJ, Reitman ZJ, et al., Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3: 709-722.
61. Cooper LA, Gutman DA, Long Q, et al., The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PloS One 2010; 5: e12548.
62. Huse JT, Phillips HS, Brennan CW,. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011; 59: 1190-1199.
63. Noushmehr H, Weisenberger DJ, Diefes K, et al., Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-522.
64. Singh D, Chan JM, Zoppoli P, et al., Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012; 337: 1231-1235.
65. Paugh BS, Qu C, Jones C, et al., Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010; 28: 3061-3068.
66. Ichimura K., Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol 2012; 29: 131-139.
67. Hartmann C, Meyer J, Balss J, et al., Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-474.
68. Horbinski C, Kofler J, Kelly LM, et al., Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009; 68: 1319-1325.
69. Yan H, Parsons DW, Jin G, et al., IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
70. Balss J, Meyer J, Mueller W, et al., Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
71. Felsberg J, Wolter M, Seul H, et al., Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010; 119: 501-507.
72. Turcan S, Rohle D, Goenka A, et al., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
73. Pollack IF, Hamilton RL, Sobol RW, et al., IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 2011; 27: 87-94.
74. Hartmann C, Hentschel B, Wick W, et al., Patients with IDH1 wild-type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-718.
75. van den Bent MJ, Dubbink HJ, Marie Y, et al., IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16: 1597-1604.
76. Wick W, Hartmann C, Engel C, et al., NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880.
77. Weller M, Felsberg J, Hartmann C, et al., Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
78. Sonoda Y, Kumabe T, Nakamura T, et al., Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 2009; 100: 1996-1998.
79. Ellezam B, Theeler BJ, Walbert T, et al., Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathol 2012; 124: 449-451.
80. Rohle D, Popovici-Muller J, Palaskas N, et al., An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630.
81. Yip S, Butterfield YS, Morozova O, et al., Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226: 7-16.
82. Labussiere M, Idbaih A, Wang XW, et al., All the 1p19q co-deleted gliomas are mutated on IDH1 or IDH2. Neurology 2010; 74: 1886-1890.
83. Xiong J, Liu Y, Wang Y, et al., Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas. Chin Med J (Engl) 2010; 123: 3566-3573.
84. Eoli M, Menghi F, Bruzzone MG, et al., Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007; 13: 2606-2613.
85. van den Bent MJ, Gravendeel LA, Gorlia T, et al., A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 2011; 17: 7148-7155.
86. Mur P, Mollejo M, Ruano Y, et al., Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. Acta Neuropathol 2013; 126: 277-289.
87. Kaloshi G, Benouaich-Amiel A, Diakite F, et al., Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007; 68: 1831-1836.
88. Cairncross G, Jenkins R,. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008; 14: 352-357.
89. Ichimura K, Pearson DM, Kocialkowski S, et al., IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009; 11: 341-347.
90. Appin CL, Gao J, Chisolm C, et al., Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. Brain Pathol 2013; 23: 454-461.
91. Ha SY, Kang SY, Do IG, et al., Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 2013; 112: 439-448.
92. Hegi ME, Janzer RC, Lambiv WL, et al., Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE.3 trial. Acta Neuropathol 2012; 123: 841-852.
93. Wang Y, Li S, Chen L, et al., Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-oncology 2012; 14: 518-525.
94. Klink B, Schlingelhof B, Klink M, et al., Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst) 2010; 33: 37-54.
95. Franco-Hernandez C, Martinez-Glez V, de Campos JM, et al., Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity. Cancer Genet Cytogenet 2009; 190: 93-96.
96. NCC N. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers, version 2: http://www.nccn.org [accessed 31 July 2013 ].
97. Ohgaki H, Dessen P, Jourde B, et al., Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
98. Liu L, Ichimura K, Pettersson EH, et al., Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. J Neuropathol Exp Neurol 1998; 57: 1138-1145.
99. Benito R, Gil-Benso R, Quilis V, et al., Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology 2010; 30: 392-400.
100. Ekstrand AJ, James CD, Cavenee WK, et al., Genes for epidermal growth factor receptor, transforming growth factor-α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-2172.
101. Frederick L, Wang XY, Eley G, et al., Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60: 1383-1387.
102. Schwechheimer K, Huang S, Cavenee WK,. EGFR gene amplification- rearrangement in human glioblastomas. Int J Cancer 1995; 62: 145-148.
103. Sugawa N, Ekstrand AJ, James CD, et al., Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990; 87: 8602-8606.
104. Zhang H, Berezov A, Wang Q, et al., ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051-2058.
105. Nishikawa R, Ji XD, Harmon RC, et al., A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-7731.
106. Soeda A, Inagaki A, Oka N, et al., Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 2008; 283: 10958-10966.
107. Houillier C, Lejeune J, Benouaich-Amiel A, et al., Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006; 106: 2218-2223.
108. Smith JS, Tachibana I, Passe SM, et al., PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246-1256.
109. Montano N, Cenci T, Martini M, et al., Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia 2011; 13: 1113-1121.
110. Bienkowski M, Piaskowski S, Stoczynska-Fidelus E, et al., Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients. PloS One 2013; 8: e65444.
111. Korshunov A, Sycheva R, Golanov A,. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer 2005; 104: 825-832.
112. Simmons ML, Lamborn KR, Takahashi M, et al., Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61: 1122-1128.
113. Feldkamp MM, Lala P, Lau N, et al., Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999; 45: 1442-1453.
114. Shinojima N, Tada K, Shiraishi S, et al., Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-6970.
115. Batchelor TT, Betensky RA, Esposito JM, et al., Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10: 228-233.
116. Hobbs J, Nikiforova MN, Fardo DW, et al., Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am J Surg Pathol 2012; 36: 1186-1193.
117. van den Bent MJ, Brandes AA, Rampling R, et al., Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 2009; 27: 1268-1274.
118. Uhm JH, Ballman KV, Wu W, et al., Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys 2011; 80: 347-353.
119. Brown PD, Krishnan S, Sarkaria JN, et al., Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008; 26: 5603-5609.
120. Hegi ME, Diserens AC, Bady P, et al., Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial. Mol Cancer Therap 2011; 10: 1102-1112.
121. Raizer JJ, Abrey LE, Lassman AB, et al., A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncology 2010; 12: 95-103.
122. Hasselbalch B, Lassen U, Poulsen HS, et al., Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling. Cancer Invest 2010; 28: 775-787.
123. Vollmann A, Vornlocher HP, Stempfl T, et al., Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. Int J Oncol 2006; 28: 1531-1542.
124. Solomon MT, Selva JC, Figueredo J, et al., Radiotherapy plus nimotuzumab or placebo in the treatment of high-grade glioma patients: results from a randomized, double-blind trial. BMC Cancer 2013; 13: 299.
125. Wesolowski JR, Rajdev P, Mukherji SK,. Temozolomide (Temodar). Am J Neuroradiol 2010; 31: 1383-1384.
126. Kaina B, Christmann M, Naumann S, et al., MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 2007; 6: 1079-1099.
127. Nakagawachi T, Soejima H, Urano T, et al., Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003; 22: 8835-8844.
128. Mellai M, Monzeglio O, Piazzi A, et al., MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. J Neurooncol 2012; 107: 617-631.
129. Nakamura M, Watanabe T, Yonekawa Y, et al., Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001; 22: 1715-1719.
130. Hegi ME, Diserens AC, Godard S, et al., Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-1874.
131. Hegi ME, Diserens AC, Gorlia T, et al., MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
132. Ohka F, Natsume A, Motomura K, et al., The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PloS One 2011; 6: e23332.
133. Preusser M, Charles Janzer R, Felsberg J, et al., Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008; 18: 520-532.
134. Weller M, Stupp R, Reifenberger G, et al., MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurology 2010; 6: 39-51.
135. Olson RA, Brastianos PK, Palma DA,. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol 2011; 105: 325-335.
136. Rivera AL, Pelloski CE, Gilbert MR, et al., MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-oncology 2010; 12: 116-121.
137. Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
138. Reifenberger G, Hentschel B, Felsberg J, et al., Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012; 131: 1342-1350.
139. Donson AM, Addo-Yobo SO, Handler MH, et al., MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediat Blood Cancer 2007; 48: 403-407.
140. Srivastava A, Jain A, Jha P, et al., MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst 2010; 26: 1613-1618.
141. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al., MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 2008; 16: 59-65.
142. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al., Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol 2011; 32: 1978-1985.
143. Jansen M, Yip S, Louis DN,. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 2010; 9: 717-726.
144. Brandes AA, Franceschi E, Tosoni A, et al., MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-2197.
145. Fabi A, Russillo M, Metro G, et al., Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Res 2009; 29: 2607-2610.
146. Jha P, Suri V, Jain A, et al., O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Neurosurgery 2010; 67: 1681-1691.
147. Sanson M, Marie Y, Paris S, et al., Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154.
148. Brandes AA, Franceschi E, Tosoni A, et al., O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro-oncology 2010; 12: 283-288.
149. Felsberg J, Thon N, Eigenbrod S, et al., Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011; 129: 659-670.